The disordered neuronal cytoskeleton in Alzheimer's disease.
about
Microtubule-associated protein/microtubule affinity-regulating kinase (p110mark). A novel protein kinase that regulates tau-microtubule interactions and dynamic instability by phosphorylation at the Alzheimer-specific site serine 262GSK-3beta is required for memory reconsolidation in adult brainThe Rps23rg gene family originated through retroposition of the ribosomal protein s23 mRNA and encodes proteins that decrease Alzheimer's beta-amyloid level and tau phosphorylationSelective modulation of amyloid-beta peptide degradation by flurbiprofen, fenofibrate, and related compounds regulates Abeta levels.Targeting Abeta and tau in Alzheimer's disease, an early interim reportInhibition of amyloidogenesis by nonsteroidal anti-inflammatory drugs and their hybrid nitratesAberrant splicing of tau pre-mRNA caused by intronic mutations associated with the inherited dementia frontotemporal dementia with parkinsonism linked to chromosome 17.Secretases as therapeutic targets for the treatment of Alzheimer's disease.Neurofibrillary degeneration in amyotrophic lateral sclerosis/parkinsonism-dementia complex of Guam. Immunochemical characterization of tau proteins.Alzheimer disease therapy: can the amyloid cascade be halted?Rous-Whipple Award Lecture. The Alzheimer's brain: finding out what's broken tells us how to fix it.The abnormal phosphorylation of tau protein at Ser-202 in Alzheimer disease recapitulates phosphorylation during development.Alzheimer disease A68 proteins injected into rat brain induce codeposits of beta-amyloid, ubiquitin, and alpha 1-antichymotrypsin.Disease modifying therapy for AD?Non-invasive, in vivo monitoring of neuronal transport impairment in a mouse model of tauopathy using MEMRINatural products as a source of Alzheimer's drug leads.Novel strategies for the prevention of dementia from Alzheimer's disease.Non-signalling energy use in the developing rat brainCurrent therapeutic targets for the treatment of Alzheimer's disease.Non-signalling energy use in the brain.Microtubule-associated protein tau, paired helical filaments, and phosphorylation.Altered tau and neurofilament proteins in neuro-degenerative diseases: diagnostic implications for Alzheimer's disease and Lewy body dementias.Regulation of tau phosphorylation in Alzheimer's disease.Site-specific dephosphorylation of tau protein at Ser202/Thr205 in response to microtubule depolymerization in cultured human neurons involves protein phosphatase 2A.Neuronal Cdc2-like kinase: from cell cycle to neuronal function.Twisted tubulofilaments of inclusion body myositis muscle resemble paired helical filaments of Alzheimer brain and contain hyperphosphorylated tau.Determination of kinetic parameters and structure-activity relationships of ginsenosides as inhibitors of cyclin-dependent kinase 5/p25 using ultra-pressure liquid chromatography with triple quadrupole tandem mass spectrometry.Glycogen synthase kinase-3 and the Alzheimer-like state of microtubule-associated protein tau.Altered CpG methylation in sporadic Alzheimer's disease is associated with APP and MAPT dysregulation.Human olfactory mucosa in schizophrenia.In situ dephosphorylation of tau by protein phosphatase 2A and 2B in fetal rat primary cultured neurons.Dephosphorylation of tau protein and Alzheimer paired helical filaments by calcmeurin and phosphatase-2A
P2860
Q24313123-A3AA7AC4-636F-4982-B7FD-1BBF22CA1E53Q28473886-EB948425-2177-46A4-917D-708AC0C09262Q28506412-6EC213B6-9B7A-4ABC-B14B-0860009C5E13Q33496258-CB4CDF0F-088C-4090-98A1-F602DF18366BQ33829008-C8898D69-B2C3-4FEA-8E8D-0D4AFE754395Q33846317-5FF87292-CB7A-4AEA-923A-399A29755935Q33963856-E32451CD-5A2B-4405-827A-0313A2EB0AF9Q34284352-90EAEACE-F7E9-43A3-8CD4-64AD685CA0A7Q34722021-78F3DAAD-1B37-45A4-9051-4BF399771B69Q34828328-36AACF92-C26B-422E-93B2-3BF861E88B15Q35085389-4EA0C5BA-AB19-49C4-AF00-B822CC503CBFQ36335067-02C015B3-5174-4E0C-A872-F3ECED13D354Q36433728-2EC4138A-AF9C-4BC3-A03A-AB5DD3B1D892Q36640414-9C17D0FA-BB8F-43D5-9B07-8E124D84ED55Q36915739-A3E5E1E6-B4DA-4EAF-B1E0-34C83511777FQ37029561-EA9AEF2C-B041-46C7-8706-4DBD86EAEE77Q37544750-95767A98-13C0-4ACE-AF8C-FA95C13A07B6Q37661826-FDD8EC8C-B419-4322-913F-0D2350E70724Q37737296-D4741201-1BBB-4078-A507-EB1EEB73B4E1Q38339583-05259375-C52F-4F43-9378-F7B7DE3D70ECQ40492240-4DCEFAB8-8378-4DFB-9F27-898082F2E8FDQ40794805-D67CFF79-4F1B-4A15-9FDE-F2A81D973256Q40983024-8AAC8772-6450-4D64-9ED7-81D7E51A50C5Q41217536-D61E8DC7-08DD-402A-AD0E-575B87808C4CQ41263650-09F5CA56-5A03-464E-B90E-D0E4212D485AQ42754605-0F60FACF-C0F2-4FC5-AE6A-EA6F87B2FC6CQ43868561-0FE06E73-520B-4A45-8E82-D35B24F68AA4Q48394153-40D4CFD4-3BDD-4E82-A2BA-6D21F29B2702Q48952606-6860F7AA-EBE2-4D90-92AA-E32E657ABC03Q52188668-1AD48DDC-6688-40CC-B7B2-7DA5B7B776FFQ52204170-B81BE0B3-BED0-4D1B-9B5C-29C0BF12C690Q58485375-4930D9C7-CED3-453D-8F16-1532D6DF37E3
P2860
The disordered neuronal cytoskeleton in Alzheimer's disease.
description
1992 nî lūn-bûn
@nan
1992 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
The disordered neuronal cytoskeleton in Alzheimer's disease.
@ast
The disordered neuronal cytoskeleton in Alzheimer's disease.
@en
type
label
The disordered neuronal cytoskeleton in Alzheimer's disease.
@ast
The disordered neuronal cytoskeleton in Alzheimer's disease.
@en
prefLabel
The disordered neuronal cytoskeleton in Alzheimer's disease.
@ast
The disordered neuronal cytoskeleton in Alzheimer's disease.
@en
P1476
The disordered neuronal cytoskeleton in Alzheimer's disease.
@en
P2093
Trojanowski JQ
P304
P356
10.1016/0959-4388(92)90034-I
P577
1992-10-01T00:00:00Z